<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124709</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981CUS09</org_study_id>
    <nct_id>NCT00124709</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification</brief_title>
  <official_title>An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Open-label Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study consists of a 3-year double-blind phase during which patients will receive atopic
      dermatitis (AD) treatment either with pimecrolimus cream 1% long-term management (LTM) or
      with a conventional corticosteroid-based treatment (1:1 ratio), followed by a 2 to 3-year
      open-label (OL) phase (all patients receiving pimecrolimus cream 1% LTM). At the end of the
      double-blind phase, the two treatment groups will be compared with respect to their efficacy
      in controlling AD; at the end of the OL phase, the incidence of asthma at the age of 6 years
      will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atopic Dermatitis (AD) Disease Control Over 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Proportion of disease-free days in Step 2 or less (per Patient) using total number of days in study as the denominator- double-blind phase. Intent to Treat Population: defined as all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Early Use of Pimecrolimus Cream 1% in Reducing the Incidence of Asthma at 6 Years of Age</measure>
    <time_frame>6 years</time_frame>
    <description>Note: The results for this efficacy variable are not reported due to early termination of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long Term Safety in Infants and Young Children</measure>
    <time_frame>6 years</time_frame>
    <description>Note: The results of this secondary outcome is not reported due to early termination of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Allergic Rhinitis, Allergic Conjunctivitis and Food Allergies</measure>
    <time_frame>6 years (36 month Double-Blind Phase)</time_frame>
    <description>Percentage of Patients who had allergic rhinitis, allergic conjunctivitis and food allergies at the end of the 36 month double blind study.
Note: The results at six years are not reported due to early termination of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid and Pimecrolimus Drug Use</measure>
    <time_frame>48 months</time_frame>
    <description>Corticosteroid and pimecrolimus study medication days of exposure during the 36 month double-blind phase.
Note: Although the double-blind phase was designed to be 36 months (3 years) in length, the last double-blind visit for some patients occurred after 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atopic Dermatitis (AD) Remission Time</measure>
    <time_frame>36 month Double-Blind Phase</time_frame>
    <description>Longest duration of atopic dermatitis (AD) remission during the 36 month double-blind treatment phase. A remission day was defined as a diary day with a positive response (&quot;yes&quot;) to the question &quot;No or almost no eczema?&quot; and a response of no treatment except emollients to the question &quot;Medication used&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient/Caregiver Quality of Life</measure>
    <time_frame>From Baseline to Visit 5 , 6, 8, 10, 12, and 14</time_frame>
    <description>Change from Baseline in the total Parents' Index of Quality of Life-Atopic Dermatitis (PIQoL-AD) score in the double-blind phase. PIQoL-AD Score = (sum of valid items/number of valid items) * 28. Scores range from a minimum value of 0 to a maximum value of 28 with a high total overall score indicating poor quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1091</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pimecrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus</intervention_name>
    <description>Pimecrolimus cream 1 %</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Elidel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>conventional corticosteroid-based treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of atopic dermatitis

          -  Family history of atopy

          -  3 to 18 months of age at baseline

          -  At least mild atopic dermatitis at baseline (investigator global assessment [IGA]
             greater or equal to 2)

          -  Clinical evidence of atopic dermatitis for no longer than 3 months

        Exclusion Criteria:

          -  Diagnosis of or substantial clinical evidence for food or other allergies at baseline

        Other protocol related criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Allergy and Asthma Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Arkansas Pediatric Clinic, P.A.</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Clinic of Jonesboro</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Dermatology Clinic and Clinical Trials Dept</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Allergy Respiratory Disease Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Medical Group of Diablo Valley, Inc./ Clinical Research Division</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates and Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerald Coast Clinical Research</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Outpatient Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rx R &amp; D</name>
      <address>
        <city>Metarie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, PLLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center/Dermatology Section</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Group</name>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12533</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of St. Luke's - Roosevelt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calcagno Research and Development</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University - Dermatology Dept.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Childrens' Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital, BCM</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Medical Group, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Granger Medical Clinic</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Inc</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2005</study_first_posted>
  <results_first_submitted>December 8, 2010</results_first_submitted>
  <results_first_submitted_qc>February 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2011</results_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Atopic, dermatitis, asthma, children, modification</keyword>
  <keyword>Atopic dermatitis/atopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pimecrolimus (Elidel) Treatment Group</title>
          <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
        </group>
        <group group_id="P2">
          <title>Control Treatment Group</title>
          <description>Management with vehicle/topical corticosteroid rescue.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="546"/>
                <participants group_id="P2" count="545"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Who Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="543"/>
                <participants group_id="P2" count="544"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="291">232 Participants entered the OL phase of the study.</participants>
                <participants group_id="P2" count="273">232 Participants entered the OL phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="272"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but did not take medication</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pimecrolimus (Elidel) Treatment Group</title>
          <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
        </group>
        <group group_id="B2">
          <title>Control Treatment Group</title>
          <description>Management with vehicle/topical corticosteroid rescue.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="543"/>
            <count group_id="B2" value="544"/>
            <count group_id="B3" value="1087"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="3.76"/>
                    <measurement group_id="B2" value="7.4" spread="4.06"/>
                    <measurement group_id="B3" value="7.3" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months to Less than 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months to Less than 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months to Less than or equal to 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parents' Index of Quality of Life - Atopic Dermatitis Score</title>
          <description>Parents' Index Quality of Life - Atopic Dermatitis (PIQoL-AD) score = (sum of valid items/number of valid items)*28. Scores range from a total possible minimum value of 0 to a maximum value of 28, with a high total overall score indicating poor quality of life.</description>
          <units>Scores on PIQoL-AD Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="4.73"/>
                    <measurement group_id="B2" value="6.9" spread="4.92"/>
                    <measurement group_id="B3" value="6.7" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Atopic Dermatitis (AD) Disease Control Over 36 Months</title>
        <description>Proportion of disease-free days in Step 2 or less (per Patient) using total number of days in study as the denominator- double-blind phase. Intent to Treat Population: defined as all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</description>
        <time_frame>36 months</time_frame>
        <population>Intent to Treat Population: all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus (Elidel) Treatment Group</title>
            <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
          </group>
          <group group_id="O2">
            <title>Control Treatment Group</title>
            <description>Management with vehicle/topical corticosteroid rescue.</description>
          </group>
        </group_list>
        <measure>
          <title>Atopic Dermatitis (AD) Disease Control Over 36 Months</title>
          <description>Proportion of disease-free days in Step 2 or less (per Patient) using total number of days in study as the denominator- double-blind phase. Intent to Treat Population: defined as all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</description>
          <population>Intent to Treat Population: all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</population>
          <units>Proportion of disease free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4404" spread="0.29876"/>
                    <measurement group_id="O2" value="0.4346" spread="0.29317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A disease-free day in Step 2 or less was defined as a diary day with variable &quot;No or almost no eczema?&quot;=yes and &quot;medication used variable&quot;=no except emollients, yellow label medication 2X day, or medication deviation of yellow label medication 1x day.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7901</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment, Center, gender, baseline age (months), baseline EASI score, and baseline TBSA as explanatory variables</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0046</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0290</ci_lower_limit>
            <ci_upper_limit>0.0381</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Early Use of Pimecrolimus Cream 1% in Reducing the Incidence of Asthma at 6 Years of Age</title>
        <description>Note: The results for this efficacy variable are not reported due to early termination of the study.</description>
        <time_frame>6 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Safety in Infants and Young Children</title>
        <description>Note: The results of this secondary outcome is not reported due to early termination of the study.</description>
        <time_frame>6 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Allergic Rhinitis, Allergic Conjunctivitis and Food Allergies</title>
        <description>Percentage of Patients who had allergic rhinitis, allergic conjunctivitis and food allergies at the end of the 36 month double blind study.
Note: The results at six years are not reported due to early termination of the study.</description>
        <time_frame>6 years (36 month Double-Blind Phase)</time_frame>
        <population>Intent to Treat Population defined as all randomized patients who were dispensed study medication and had at least one post-baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus (Elidel) Treatment Group</title>
            <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
          </group>
          <group group_id="O2">
            <title>Control Treatment Group</title>
            <description>Management with vehicle/topical corticosteroid rescue.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Allergic Rhinitis, Allergic Conjunctivitis and Food Allergies</title>
          <description>Percentage of Patients who had allergic rhinitis, allergic conjunctivitis and food allergies at the end of the 36 month double blind study.
Note: The results at six years are not reported due to early termination of the study.</description>
          <population>Intent to Treat Population defined as all randomized patients who were dispensed study medication and had at least one post-baseline efficacy measurement.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="532"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diagnosis of Food Allergy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosis of Allergic rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnosis of Allergic conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corticosteroid and Pimecrolimus Drug Use</title>
        <description>Corticosteroid and pimecrolimus study medication days of exposure during the 36 month double-blind phase.
Note: Although the double-blind phase was designed to be 36 months (3 years) in length, the last double-blind visit for some patients occurred after 36 months.</description>
        <time_frame>48 months</time_frame>
        <population>Safety population: all randomized patients who were dispensed study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus (Elidel) Treatment Group</title>
            <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
          </group>
          <group group_id="O2">
            <title>Control Treatment Group</title>
            <description>Management with vehicle/topical corticosteroid rescue.</description>
          </group>
        </group_list>
        <measure>
          <title>Corticosteroid and Pimecrolimus Drug Use</title>
          <description>Corticosteroid and pimecrolimus study medication days of exposure during the 36 month double-blind phase.
Note: Although the double-blind phase was designed to be 36 months (3 years) in length, the last double-blind visit for some patients occurred after 36 months.</description>
          <population>Safety population: all randomized patients who were dispensed study medication.</population>
          <units>Days of Exposure</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double -blind phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.8" spread="259.49"/>
                    <measurement group_id="O2" value="249.6" spread="251.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-12 months (Year 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.6" spread="105.75"/>
                    <measurement group_id="O2" value="147.6" spread="112.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-24 months (Year 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="105.08"/>
                    <measurement group_id="O2" value="65.0" spread="97.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-36 months (Year 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="83.65"/>
                    <measurement group_id="O2" value="36.6" spread="76.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>37-48 months (Year 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="5.74"/>
                    <measurement group_id="O2" value="1.0" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atopic Dermatitis (AD) Remission Time</title>
        <description>Longest duration of atopic dermatitis (AD) remission during the 36 month double-blind treatment phase. A remission day was defined as a diary day with a positive response (&quot;yes&quot;) to the question &quot;No or almost no eczema?&quot; and a response of no treatment except emollients to the question &quot;Medication used&quot;.</description>
        <time_frame>36 month Double-Blind Phase</time_frame>
        <population>Intent-to-Treat population: all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus (Elidel) Treatment Group</title>
            <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
          </group>
          <group group_id="O2">
            <title>Control Treatment Group</title>
            <description>Management with vehicle/topical corticosteroid rescue.</description>
          </group>
        </group_list>
        <measure>
          <title>Atopic Dermatitis (AD) Remission Time</title>
          <description>Longest duration of atopic dermatitis (AD) remission during the 36 month double-blind treatment phase. A remission day was defined as a diary day with a positive response (&quot;yes&quot;) to the question &quot;No or almost no eczema?&quot; and a response of no treatment except emollients to the question &quot;Medication used&quot;.</description>
          <population>Intent-to-Treat population: all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.9547" spread="137.61350"/>
                    <measurement group_id="O2" value="117.1071" spread="150.33993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient/Caregiver Quality of Life</title>
        <description>Change from Baseline in the total Parents' Index of Quality of Life-Atopic Dermatitis (PIQoL-AD) score in the double-blind phase. PIQoL-AD Score = (sum of valid items/number of valid items) * 28. Scores range from a minimum value of 0 to a maximum value of 28 with a high total overall score indicating poor quality of life.</description>
        <time_frame>From Baseline to Visit 5 , 6, 8, 10, 12, and 14</time_frame>
        <population>Intent-to-Treat Population: all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pimecrolimus (Elidel) Treatment Group</title>
            <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
          </group>
          <group group_id="O2">
            <title>Control Treatment Group</title>
            <description>Management with vehicle/topical corticosteroid rescue.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient/Caregiver Quality of Life</title>
          <description>Change from Baseline in the total Parents' Index of Quality of Life-Atopic Dermatitis (PIQoL-AD) score in the double-blind phase. PIQoL-AD Score = (sum of valid items/number of valid items) * 28. Scores range from a minimum value of 0 to a maximum value of 28 with a high total overall score indicating poor quality of life.</description>
          <population>Intent-to-Treat Population: all randomized patients who were dispensed study medication and had at least one post baseline efficacy measurement.</population>
          <units>Scores on PIQoL-AD Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Baseline to Visit 5 (Week 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="3.67"/>
                    <measurement group_id="O2" value="-2.3" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline to Visit 6 (Week 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="3.84"/>
                    <measurement group_id="O2" value="-2.7" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline to Visit 8 (Week 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.97"/>
                    <measurement group_id="O2" value="-3.1" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline to Visit 10 (Week 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="4.13"/>
                    <measurement group_id="O2" value="-3.5" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline to Visit 12 (Week 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="4.15"/>
                    <measurement group_id="O2" value="-3.6" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline to Visit 14 (Week 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="4.28"/>
                    <measurement group_id="O2" value="-3.8" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pimecrolimus (Elidel) Treatment Group</title>
          <description>Pimecrolimus (Elidel) 1% Cream twice a day/topical corticosteroid rescue</description>
        </group>
        <group group_id="E2">
          <title>Control Treatment Group</title>
          <description>Management with vehicle/topical corticosteroid rescue.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Von Willebrand's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Croup, infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Tonsillitis, streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Beta hemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Eczema, infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Laryngotracheo bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Pneumonia, bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Hepatic trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Nephroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prepuce redundant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Bronchial hyper-reactivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Epiglottic edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="482" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="467" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis, allergic</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="288" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="260" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Conjunctivitis, bacterial</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="544"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="543"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="544"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

